DDInter758 DDInter927
Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Fluoxetine {u} (Compound) resembles {v} (Compound) Orphenadrine
Fluoxetine {u} (Compound) resembles {v} (Compound) Duloxetine
Fluoxetine {u} (Compound) binds {v} (Gene) CYP2D6
Fluoxetine {u} (Compound) upregulates {v} (Gene) ALDOC
Fluoxetine {u} (Compound) palliates {v} (Disease) schizophrenia
Fluoxetine {u} (Compound) downregulates {v} (Gene) RPS4Y1
Fluoxetine {u} (Compound) causes {v} (Side Effect) Cystitis
Fluoxetine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Fluoxetine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Levothyroxine
Fluoxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mepyramine
Fluoxetine (Compound) resembles Orphenadrine (Compound)
Fluoxetine (Compound) resembles Duloxetine (Compound)
Fluoxetine (Compound) binds CYP2D6 (Gene)
Fluoxetine (Compound) upregulates ALDOC (Gene)
Fluoxetine (Compound) palliates schizophrenia (Disease)
Fluoxetine (Compound) downregulates RPS4Y1 (Gene)
Fluoxetine (Compound) causes Cystitis (Side Effect)
Fluoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Fluoxetine may cause a minor interaction that can limit clinical effects when taken with Levothyroxine
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine